Factors Influencing Disease-Free Survival in Breast Cancer Patients Treated with Neoadjuvant Chem-otherapy Combined with Modified Radical Mastectomy
[Objective]To explore the factors influencing disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy combined with modified radical mastectomy.[Methods]A total of 150 breast cancer patients trea-ted in our hospital,who underwent modified radical mastectomy combined with neoadjuvant chemotherapy,were followed up for 3 years.The endpoint of follow-up was tumor metastasis,recurrence,or death.Patients with disease-free survival of less than 3 years were classified as the poor prognosis group(n=29),while those with disease-free survival of 3 years or more were classified as the good prognosis group(n=121).General data of the two groups were collected,and univariate and multivariate analyses were used to identify factors influencing disease-free survival.[Results]During the 3-year follow-up of 150 patients,16 deaths were recorded,giving an overall survival rate of 89.33％(134/150).There were 6 cases of re-currence and 7 cases of metastasis,resulting in a disease-free survival rate of 80.67％(121/150).The proportion of patients aged ≤45 years,premenopausal status,tumor size＞5 cm,clinical stage T3 or T4,positive vascular tumor embolvs,ab-sence of postoperative radiotherapy,negative estrogen receptor(ER)/progesterone receptor(PR)status,and Ki67 index＞30％were significantly higher in the poor prognosis group compared to the good prognosis group(P＜0.05).Multivariate logistic regression analysis confirmed that these factors above were risk factors affecting postoperative disease-free survival(P＜0.05).[Conclusion]Age ≤45 years,premenopausal status,tumor size＞5 cm,clinical stage T3 or T4,positive vascular tumor thrombus,absence of postoperative radiotherapy,negative ER/PR status,and Ki67 index＞30％are risk factors affecting disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy combined with modi-fied radical mastectomy.
Breast Neoplasms/SUChemotherapy,AdjuvantDisease-Free Survival
万方数据
维普
